Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18053 ↗Kurz gefasst
Editorial in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Stephanie A Vuijk und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Cost-Benefit Analysis, Gastrointestinal Agents. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
LINKED CONTENT This article is linked to Vuijk et al papers. To view these articles, visit https://doi.org/10.1111/apt.18000 and https://doi.org/10.1111/apt.18033
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands.
ORCID-Profile: Stephanie A Vuijk, Lissy de Ridder
Zitieren
APA
Vuijk, S. A., & de Ridder, L. (2024). Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18053
Vancouver
Vuijk SA, de Ridder L. Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18053
BibTeX
@article{Vuijk2024,
author = {Vuijk, Stephanie A and de Ridder, Lissy},
title = {Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18053}
}
EUVIMED